We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease

By LabMedica International staff writers
Posted on 20 Nov 2026

Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify disease-associated signals from small sample volumes, but exosome detection can be complicated by interference from other molecules in the blood. To overcome this limitation, researchers have developed an experimental diagnostic platform that screens for all four diseases using 10 microliters of blood in about one hour.

Researchers at the University of Notre Dame developed the patent-pending diagnostic platform using immunojanus particles, tiny spheres with two chemically distinct halves. One side is coated with antibodies that bind disease-associated targets, while the other is fluorescent and provides a detectable signal. The platform is designed to identify exosomes in blood that carry proteins associated with disease.


Image: A model of an immunojanus particle, a technology developed by Chang and his lab for disease detection (Photo courtesy of Hsueh-Chia Chang/University of Notre Dame)
Image: A model of an immunojanus particle, a technology developed by Chang and his lab for disease detection (Photo courtesy of Hsueh-Chia Chang/University of Notre Dame)

To perform the test, blood is diluted with saline and mixed with the immunojanus particles for 10 to 60 minutes. As the particles disperse through the sample, their antibodies bind to disease-specific proteins on the surface of exosomes. The sample is then examined under a microscope, where proprietary software analyzes the particles’ Brownian motion to determine whether a disease-associated marker is present.

The platform was evaluated in a blind setting using 87 plasma samples from blood draws from healthy individuals and patients with one of the four diseases. It showed 90% to 99% accuracy for detecting the presence or absence of each disease type. The study, “Rapid and sensitive detection of cancer-derived small extracellular vesicles using Janus particles,” was published in Nature Biomedical Engineering

The method is described as fast and low-cost, and as more accurate than the leading exosome detection technology. Its design addresses interference by combining sensitivity to single exosome binding with selectivity against other small molecules. “We believe that if we can screen these diseases earlier, then patients may have a better chance at surviving,” said Hsueh-Chia Chang, the Bayer Corporation professor of engineering in the Department of Chemical and Biomolecular Engineering at Notre Dame. 

“We had to overcome the interference issue, and immunojanus particles can because they are both sensitive and selective. Sensitive because we can detect a single exosome on an immunojanus particle from the blinking frequency, and selective because other small molecules do not produce a signal,” added Chang.

Related Links
University of Notre Dame


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)

Latest Technology News

New qPCR Master Mixes Offer Broad Compatibility for Routine Research
20 Nov 2026  |   Technology

Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
20 Nov 2026  |   Technology

Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
20 Nov 2026  |   Technology